Preserving fertility and optimising care for the one in seven women suffering from endometriosis
SINGAPORE, May 1, 2025 /PRNewswire/ -- Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help preserve the fertility of those with the debilitating condition.
They have finalised a rigorous consensus process to create a defined and auditable standard for networks of expertise for endometriosis treatment for the one in seven females of reproductive age living with the chronic pelvic pain and fertility risk from the disease.
It sets a gold standard of patient-centred care for sufferers of endometriosis and a similar condition called adenomyosis while considering the diversity of countries, economies, cultures and societies in the APAC region.
The experiences and views of patients living with endometriosis and adenomyosis have been incorporated in developing the consensus structure.
Endometriosis occurs when tissue similar to the inner lining of the uterus grows outside the uterus. It often affects the ovaries, fallopian tubes and the tissue lining the pelvis. Currently, there is no absolute preventive strategy or cure for the condition, but treatment options can help manage its chronic impacts.
The new approaches to endometriosis treatment will be outlined this week at the 2025 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Singapore.
The Congress from today (1 May) to Sunday has brought together over 2,000 scientists, clinicians, nurses and counsellors for a program that will help shape the future of fertility health care in the region and around the world.
New Zealand fertility specialist Professor Neil Johnson, an ASPIRE Board member and Past President of the World Endometriosis Society, has led the endometriosis consensus program with international specialists in the field.
"The topics covered and the way that they have been addressed set new world standards in care, and our hope is that they will influence policy makers and those responsible for health funding decisions," Professor Johnson explained.
"My aspiration for the networks of expertise consensus is that it presents what our APAC experts believe to be the optimal model of how complex multidisciplinary care in endometriosis should be best structured.
"Currently, there is a wide variation in the quality of multidisciplinary care for endometriosis. In many settings, care is provided without the key structures and enmeshment that is crucial for coordinated patient care.
"This consensus has the potential to become an accreditation gold standard. It may then be possible to assess the calibre of endometriosis care services across APAC to determine whether they meet the ASPIRE standard to be defined as a network of expertise.
"The consensus on fertility preservation in endometriosis is an issue that has come into sharp focus. In the past, repeated ovarian surgery for endometriosis sufferers has meant that some patients have ended up with extremely low ovarian reserve, which refers to the quantity of eggs remaining in the ovaries with egg quality often negatively affected by endometriosis.
"In some cases, ovarian reserve has become so low that it is very difficult for these patients to achieve a pregnancy either through natural conception or medically assisted reproduction. This is a tragic outcome for young women.
"Our consensus emphasises the need for awareness that endometriosis itself can compromise ovarian reserve along with the impact of ovarian surgery.
"It highlights the importance of blood testing for anti-mullerian hormone (AMH) levels and ovarian ultrasound for antral follicle count to accurately measure a patient's ovarian reserve.
"Timing of pregnancy is another important consideration. While it is a personal choice, the ability to conceive may be affected by a decision to delay attempts to become pregnant.
"Of prime importance is the provision of information on fertility preservation to endometriosis sufferers no later than in their twenties. This is vital for patients with severe (stage IV) endometriosis or those facing ovarian surgery.
"Fertility preservation is typically through egg freezing, although embryo freezing might be preferred by some couples in committed relationships.
"Ovarian tissue freezing may be considered in exceptional cases for endometriosis. Typically, this is an option for cancer patients facing potentially sterilising chemotherapy in the oncology setting. However, more research is needed to explore the role of ovarian tissue freezing for those with endometriosis.
"Finally, our consensus teams highlight the importance of integrating psychological support and overall fertility counselling as a critical aspect of care.
The ASPIRE 2025 Congress is being held at the Suntec Convention and Exhibition Centre in Singapore. For further information, go to
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
2 days ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.

Korea Herald
3 days ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact


Korea Herald
4 days ago
- Korea Herald
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.